BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer

NEW YORK, March 27, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, announced today the appointment of Edward Dongheng Liu as Chief Financial Officer of the Company, effective immediately.

“Edward’s extensive experience over the years in key leadership roles at Epiphron Capital, Jefferies and J.P. Morgan makes him a perfect fit for our team,” said Dr. Lan Huang, BeyondSpring CEO. “With 2018 set to be a milestone year for BeyondSpring’s first-in-class, lead asset, Plinabulin, the deep industry knowledge that Edward brings to BeyondSpring comes at an opportune time. His distinct blend of healthcare and in-depth financial expertise will be a key addition to the leadership team’s collective experience as we advance toward our goal to submit New Drug Applications in China around year-end 2018 / early 2019, and in the U.S. beginning in 2019.”

Mr. Liu has more than a decade of senior banking experience, having served in roles of increasing responsibility at J.P. Morgan and Jefferies, where he supported dozens of initial public offerings, share placements, bond offerings, mergers and acquisitions. Prior to joining BeyondSpring, he served as partner and executive director at Epiphron Capital, an early investor in BeyondSpring.

“The invaluable skillset and financial acumen that Edward brings to the table is further enhanced by his familiarity with BeyondSpring’s unique story as an investor in the Company for the past two years,” added Dr. Huang. “In positioning Plinabulin to transform multiple therapeutic indications, we are focused on building the most strategic, data-driven team possible, and bringing Edward on board during such a pivotal moment in BeyondSpring’s history represents a critical piece in making our mission a reality.”

Mr. Liu received his bachelor’s degree in economics and mathematics from Yale University. He also studied biomedical engineering at Tsinghua University.

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to global market.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the Company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Relations:
Caitlin Kasunich / Kathryne Hunter
KCSA Strategic Communications
212.896.1241 / 212.896.1204
[email protected] / [email protected]

Investor Relations:
Laura Perry / Joe Rayne
Argot Partners
212.600.1902
[email protected]